Voyager Therapeutics Inc $ 11.19 -0.01 (-0.09%)
Volume:
262,959
Avg Vol (1m):
307,450
Market Cap $:
418.84 Mil
Enterprise Value $:
198.61 Mil
P/E (TTM):
0.00
P/B:
5.16
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 7.51 | ||
| Equity-to-Asset | 0.25 | ||
| Debt-to-Equity | 0.42 | ||
| Debt-to-EBITDA | -0.76 | ||
| Piotroski F-Score | 2 | ||
| Altman Z-Score | 0.26 | ||
| Beneish M-Score | 6.42 | ||
| WACC vs ROIC | |||
Profitability Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -39.93 | ||
| Net Margin % | -34.7 | ||
| ROE % | -40.17 | ||
| ROA % | -10.98 | ||
| ROC (Joel Greenblatt) % | -103.87 | ||
| 3-Year Revenue Growth Rate | 73 | ||
| 3-Year EBITDA Growth Rate | 5.4 | ||
| 3-Year EPS without NRI Growth Rate | 8.7 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 5.16 | ||
| PS Ratio | 3.56 | ||
| EV-to-EBIT | -4.23 | ||
| EV-to-EBITDA | -4.55 | ||
| EV-to-Revenue | 1.69 | ||
| Current Ratio | 3.76 | ||
| Quick Ratio | 3.76 | ||
| Days Sales Outstanding | 50.68 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.9 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.18 | ||
| Earnings Yield (Greenblatt) % | -23.62 |